AT-121 NEW
| Price | $350 | $828 | $1130 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-20 |
Product Details
| Product Name: AT-121 | CAS No.: 2099681-31-7 |
| Purity: 99.97% | Supply Ability: 10g |
| Release date: 2026/04/20 |
Product Introduction
Bioactivity
| Name | AT-121 |
| Description | AT-121 is a dual μ-opioid and neuropeptide receptor partial agonist (Kis 16.49 and 3.67 nM, respectively). It stimulates [35S]GTPγS binding to cell membranes expressing either μ-opioid receptors or neuropeptide receptors (EC50s of 19.6 and 34.7 nM, respectively.) AT-121 (0.003-0.03 mg/kg) reduced capsaicin-induced thermal anisocoria in a dose-dependent manner, but did not increase scratching activity in rhesus monkeys. In rhesus monkey drug self-administration tests, AT-121 at doses of 0.3 to 10 μg/kg per injection lacked reinforcing effects (a potential marker of abuse) and did not reduce the reinforcing effects of food pellets.AT-121 (0.01 or 0.03 mg/kg) did not induce hyperalgesia, a marker of tolerance, in rhesus monkeys.AT-121 is a safe non-addictive pain reliever with anti-injury and analgesic effects. |
| In vivo | AT-121 (0.003-0.03 mg/kg; s.c.; rhesus monkeys) decreases capsaicin-induced thermal allodynia dose-dependently without increasing scratching activity or inducing hyperalgesia, a marker of tolerance development, in doses of 0.01 or 0.03 mg/kg in rhesus monkeys. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (118.88 mM), Sonication is recommended. Chloroform : 9 mg/mL (19.45 mM), Sonication is recommended. DMF : Miscible Ethanol : Miscible Ethanol:PBS (pH 7.2) (1:20) : 50 μg/mL, Sonication is recommended. |
| Keywords | μ-opioid receptor | OpioidReceptor | Opioid Receptor | AT-121 | AT121 | AT 121 |
| Inhibitors Related | Docusate sodium | Bevenopran | Mirtazapine | Matrine | (-)-Menthol | Cuminaldehyde | Progesterone | Naltrexone hydrochloride | Cebranopadol | BTRX-335140 | Bisacodyl | Mianserin hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY